OUR FOCUS

PURSUE

Innovative science and solutions that expand access to valued treatments.

DEVELOP

Transformative therapies for rare diseases with high unmet needs.

DELIVER

With the urgency patients require and the precision health systems demand.

December 30, 2019

Effective December 27, 2019, DSP has acquired from Roivant 100% of “Sumitovant Biopharma,” a newly formed company, and Roivant’s ownership interest in the five subsidiary companies, including Enzyvant, that comprise Sumitovant.

November 1, 2019

Under a definitive agreement signed yesterday, DSP will acquire Roivant’s ownership interest in Enzyvant and four other Roivant companies with promising pipelines.

Contact us for more information